Pharma & Bio
Lifestyle
SEERS Sold for 1,000 Won, Net Profit of 440 Won... Pharmaceuticals, Biotech, and Healthcare Rank 'Top in Profitability'
#SEERS Technology is rapidly emerging as the most profitable company among domestic pharmaceutical, biotech, and healthcare firms. In the first half of this year, the company generated 26.8 billion wo…
Technology
Curiox Hits Limit-Up; CPS Overhang Weighs on OliX [K-Bio Pulse]
On Aug. 14, Curiox Biosystems hit the daily upper limit after announcing a “multi-unit” order from a global pharmaceutical company. OliX Pharmaceuticals, meanwhile, extended its losing streak to four …
Technology
Curiox Rises on 'Multi-Unit' Order… Olix Pharmaceuticals, Inc. Hindered by CPS Overhang [Bio Spotlight]
On the 14th, in the biotech and healthcare sector, Curiox hit the daily price limit following news that it had secured a “multi-unit” order from a global pharmaceutical company. Meanwhile, Olix Pharma…
Lifestyle
Park Dong-hyun, CEO of Mezion Pharma Co., Ltd.: “A 20-Year Battle for Udenafil… Moving Beyond Fontan to ADPKD”
“While developing Udenafil over the past 20 years, we reviewed countless other new drug candidates. But in the end, we couldn’t find a compound as promising as this one.”Park Dong-hyun, CEO (Chairman)…
Technology
A Closer Look at Kori Group’s Financial Statements Amid the ‘Accounts Receivable Controversy’… Operating Cash Flow Deficit Persists
Screenshot of the Cory Group website.
As concerns arise over the possibility that Beijing Hanmi, a Chinese subsidiary of Hanmi Group, may be unable to collect its accounts receivable, attention is…
Technology
JWPHARMACEUTICAL Goes Head-to-Head with 6mg ‘Gout Treatment’… Global Competition Also Accelerates
(Graphic: Generative AI)
JWPHARMACEUTICAL(001060)’s new gout drug candidate, “Efamynurad,” has demonstrated its competitiveness at the 6 mg dose—its primary dosage—in a multinational Phase 3 clini…
Technology
BioNexus, a Company in the Government’s Spotlight: CEO Kim Tae-hyung Says, “AI Formulates Hypotheses and Conducts Experiments… It’s Revolutionizing New Drug Development”
Advances in artificial intelligence (AI) are reshaping the process of new drug development. Whereas researchers used to read papers and formulate hypotheses, AI now reads hundreds of thousands of pape…
Technology
BlackRock, Which Suffered Losses with SillaJen and Helixmith: Will Its Latest Bet on K-Bio Pay Off?
BlackRock’s headquarters in New York, U.S. (Photo: Newsis.)
Interest is mounting in the reasons behind BlackRock, the world’s largest asset management firm, expanding its investments in South Kore…
Technology
Why SK BIOPHARMACEUTICALS Is Staking Its Future on Securing IP... The Evergreening Gamble
SK BIOPHARMACEUTICALS’ New Epilepsy Drug Excofry (Photo courtesy of SK BIOPHARMACEUTICALS)
The success or failure of new drug development no longer ends with obtaining approval. “IP management” ha…
Lifestyle
[Exclusive] ECM Skin Booster: Side Effect Reporting Requirements Tightened to “Twice a Year”… Regulatory Framework Outline
As cell-free allogeneic dermal-based extracellular matrix (ECM) skin boosters are reshaping the market, regulatory authorities are taking steps to strengthen safety measures. Rather than creating a ne…